(KITE) - Earnings & Price History

KITE: - 179.79, $10.28B, 0.00 (0.00%)

Sector: Healthcare - Industry: Biotechnology

Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate is KTE-C19, a chimeric antigen receptors (CAR)-based therapy that is in Phase 2 clinical trials for the treatment of patients with refractory diffuse large B cell lymphoma, including primary mediastinal B cell lymphoma and transformed follicular lymphoma. The company is also conducting a Phase 2 clinical trial of KTE-C19 on patients with relapsed/refractory mantle cell lymphoma; a Phase 1-2 clinical trial of KTE-C19 on adult patients with relapsed/refractory acute lymphoblastic leukemia; and a Phase 1-2 clinical trial of KTE-C19 in pediatric patients with

Past KITE reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2017-02-28BMO-1.7570.7756.8356.8362.3372.824.53%24.53%9.70M
2017-02-27BMO-1.7556.8352.653.9252.55572.51%5.40%8.04%1.19M
2016-11-09BMO-1.6249.6145.5748.6547.0449.886.76%▲1.97%8.87%2.90M
2016-08-08AMC-1.2159.258.2556.4956.0259.96-3.02%4.80%1.63%943.69K
2016-05-09AMC-1.0845.7845.844.2143.947.3-3.47%3.55%-0.04%799.73K
2016-02-29AMC-0.7151.244.7244.0343.152.22-1.54%16.28%14.49%2.67M
2015-11-12-0.6481.3381.6480.9978.3585.31-0.80%▲0.42%-0.38%1.22M
2015-08-10AMC-0.466.0767.8565.2862.6969.32-3.79%1.21%-2.62%1.12M
2015-05-150.12
2015-04-210.2857.5658.9958.857.559.28-0.32%-2.11%-2.42%861.52K
2015-03-26BMO-0.257.7562.2759.6554.7261.42-4.21%-3.19%-7.26%3.13M
2014-11-13Kite Pharma Inc-0.23-0.2439.3440.8540.6437.7641.56-0.51%▲-3.20%-3.70%543.40K

Login | Register
Saturday Nov 18, 2017   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades